New depression drug moves to Long-Term safety check in 1,000 patients
Disease control
Recruiting now
This study is for adults with major depressive disorder who have already completed a shorter trial of the investigational drug NMRA-335140. Over 52 weeks, researchers will monitor safety and how well the drug continues to work. The goal is to see if this medication can be a safe,…
Phase: PHASE3 • Sponsor: Neumora Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC